Literature DB >> 9604127

Rationale for influx enhancement versus efflux blockade to increase drug exposure to the brain.

P L Golden1, G M Pollack.   

Abstract

Various methods of optimizing brain exposure to polar compounds have been examined. However, direct comparisons of the potential efficacy of these methods have not been forthcoming. The present study utilized a mathematical approach to compare the efficacy of two pharmacologic methods of improving brain drug distribution: uptake enhancement and efflux blockade. In the present simulation study, the pharmacokinetics of a hypothetical marker and modifier were described by differential equations. The relationship between modifier effect on marker uptake into, or efflux from, the brain and modifier concentration in serum (uptake enhancement) or brain tissue (efflux blockade) was described by the Hill equation. Uptake enhancement increased both the rate and extent of marker penetration into the brain. Efflux blockade resulted in delayed attainment of maximum marker concentration, and prolonged marker residence, in brain tissue. Under all conditions and doses examined, uptake enhancement was more effective than efflux blockade in maximizing brain tissue exposure to the marker. Although development of agents that enhance uptake of polar compounds may be limited by the potential deleterious effects of blood-brain barrier disruption, use of this approach in theory could represent a significant advancement in the treatment of brain disorders.

Entities:  

Mesh:

Year:  1998        PMID: 9604127     DOI: 10.1002/(sici)1099-081x(199805)19:4<263::aid-bdd104>3.0.co;2-4

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  5 in total

1.  Pharmacokinetic consequences of active drug efflux at the blood-brain barrier.

Authors:  Stina Syvänen; Rujia Xie; Selma Sahin; Margareta Hammarlund-Udenaes
Journal:  Pharm Res       Date:  2006-04-07       Impact factor: 4.200

2.  Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecid-sensitive transport.

Authors:  R Xie; M R Bouw; M Hammarlund-Udenaes
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

Review 3.  Challenges of using in vitro data for modeling P-glycoprotein efflux in the blood-brain barrier.

Authors:  Noora Sjöstedt; Hanna Kortejärvi; Heidi Kidron; Kati-Sisko Vellonen; Arto Urtti; Marjo Yliperttula
Journal:  Pharm Res       Date:  2014-01       Impact factor: 4.200

Review 4.  On the rate and extent of drug delivery to the brain.

Authors:  Margareta Hammarlund-Udenaes; Markus Fridén; Stina Syvänen; Anubha Gupta
Journal:  Pharm Res       Date:  2007-12-05       Impact factor: 4.200

Review 5.  Strategies for increasing drug delivery to the brain: focus on brain lymphoma.

Authors:  Tali Siegal; Ester Zylber-Katz
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 5.577

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.